Table 1.

Clinical results at 1 year in major randomized trials with coronary stenting

		Angiographic restenosis
Study/Procedure	n	rate (%)	Death (%)	MI (%)	CABG (%)	PTCA (%)	MACE (%)
BENESTENT [13,17]
Stent	259	22*	1.2	3.5	6.9	10.0*	23.2*
PTCA	257	32	0.8	1.9	5.1	20.6	31.5
STRESS [14,38]
Stent	205	32*	1.5	3.4	5.8	15.1	21.0
PTCA	202	42	2.0	3.5	8.9	16.4	26.2
BENESTENT II [35]
Stent (heparin coated)	413	16*	1.0	1.9	1.9	9.4*	15.7*
PTCA	410	31	1.0	1.5	1.5	15.6	22.4
EPISTENT [11]
Stent + abciximab	794	31†	1.0	4.4	5.8	13.6*	18.6*
PTCA + abciximab	796	40	2.1	6.4	6.3	18.3	24.9
ARTS [39]
Stent	600	N/A	2.5	5.3	4.7*	12.2*	26.3*
CABG	605	N/A	2.8	4.0	0.5	3.0	12.2

Study acronyms are defined in the text. ^*P < 0.05 for the comparison between stent and respective control arm (PTCA or CABG). ^†Restenosis data presented at the 48^th Annual Scientific Session of the American College of Cardiology, New Orleans, LA, USA, 1999. MACE, any major adverse clinical event; MI, myocardial infarction (defined as either Q-wave infarction or creatine kinase elevation ≥ 5 times the upper normal limit); N/A, not available.